Casdin Capital, LLC's Form 4 filing
Tenaya Therapeutics, Inc. (TNYA) · filed Aug 4, 2021
- Accession no.
- 0001209191-21-049765
- Filed
- Aug 4, 2021, 6:33 PM ET
- Trade date
- Aug 3, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $12.8M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Casdin Capital, LLCCIK 0001534261 | 10% Owner |
| Casdin Partners Master Fund, L.P.CIK 0001534265 | 10% Owner |
| Casdin Private Growth Equity Fund, L.P.CIK 0001823061 | 10% Owner |
| Casdin Private Growth Equity Fund GP, LLCCIK 0001864554 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2021 | Common Stock | CConversionAcquired | +2,374,849 | $0.00 | $0 | 2,374,849 | Indirect | Duplicate filing |
| Aug 3, 2021 | Common Stock | PPurchaseAcquired | +850,000 | $15.00 | +$12,750,000 | 3,224,849 | Indirect | Duplicate filing |
| Aug 3, 2021 | Common Stock | CConversionAcquired | +361,969 | $0.00 | $0 | 361,969 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2021 | Common Stock | CConversionDisposed | −2,012,880 | –F4 | – | 0 | Indirect | Duplicate filing |
| Aug 3, 2021 | Common Stock | CConversionDisposed | −361,969 | –F4 | – | 0 | Indirect | Duplicate filing |
| Aug 3, 2021 | Common Stock | CConversionDisposed | −361,969 | –F4 | – | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date.
Referenced by the price of 3 transactions in Table II.